Tecan Group AG
273.20
EUR
+8.80
(+3.33%)
ISIN
CH0012100191
Return %
Stock
S&P 500
1Y
66.89
14.20
3Y
-5.99
81.12
5Y
- -
68.34
Capital Structure
CHF
•
in mil. unless spec.Working Capital
CHF
•
in mil. unless spec.Growth Rates
CHF
•
in mil. unless spec.Semi-annual Revenue
CHF
•
in mil. unless spec.Semi-annual Earnings Per Share
CHF
•
in mil. unless spec.Semi-annual Dividends Per Share
CHF
•
in mil. unless spec.Company Description
- CEO
- Monica Del Carmen Manotas Urueta
- Full Time Employees
- 3,244
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- Seestrasse 103 Maennedorf ZH Switzerland 8708
- IPO Date
- May 4, 2001
- Website
- tecan.com
- Similar Companies
- Business
- Tecan Group AG Tecan Group AG develops, manufactures and markets automated laboratory instruments, workflow solutions and components primarily for life sciences research, biopharmaceuticals, forensics, applied markets and clinical diagnostics. The company offers liquid handling and robotics platforms including the Fluent, Freedom EVO, Veya and Duo systems; analytical benchtop readers and washers; microarray products such as scanners and hybridization stations; HP D300 digital dispensers; sample management systems; immunoassay reagents for infectious diseases, autoimmunity, neurodegeneration, endocrinology and food intolerance; smart consumables like disposable tips, microplates and reagent troughs; software packages such as FluentControl; and OEM services through Synergence, Cavro and Paramit brands encompassing custom instruments, components and contract manufacturing. Tecan operates globally with primary revenue from the Americas and Europe, supplemented by presence in Asia-Pacific including sites in China, Singapore, Australia and Malaysia, as well as Europe and the US; the company, founded in 1980, maintains headquarters in Männedorf, Switzerland. Recent developments include the acquisition of ELISA immunoassay assets from Cisbio Bioassays in April 2025 to expand specialty diagnostics offerings; a partnership with Grifols announced in Q1 2025 for biomarker panels leveraging single molecule counting technology; new manufacturing contracts such as one with a global diagnostics firm via Paramit and expanded production of a proteomics platform; a collaboration with a MedTech firm in women's health advancing to deliveries from Penang by end-2025; and shipments commencing for a next-generation diagnostic instrument family developed with a key Synergence partner.
Company News
Update zum 1. Quartal 2026: Tecan auf Kurs mit Umsatzwachstum im niedrigen einstelligen Bereich in Lokalwährungen; Ausblick für das Gesamtjahr 2026 bestätigt
Q1 2026 Update: Tecan on track with low-single-digit local currency growth in Q1; full-year 2026 outlook confirmed
Camila Japur joins Tecan as Chief Financial Officer
Tecan presents 2025 results and provides details on program to reignite profitable growth
Tecan präsentiert Ergebnisse 2025 und stellt Programm zur Rückkehr zu profitablem Wachstum vor
Tecan meldet Rückkehr zum Umsatzwachstum und starken Auftragseingang im zweiten Halbjahr 2025
Tecan reports return to sales growth and strong order entry in the second half of 2025